Literature DB >> 11248009

Calcineurin inhibition and cardiac hypertrophy: a matter of balance.

L A Leinwand1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11248009      PMCID： PMC33335          DOI： 10.1073/pnas.051033698

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  18 in total

1.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.

Authors:  M Shimoyama; D Hayashi; E Takimoto; Y Zou; T Oka; H Uozumi; S Kudoh; F Shibasaki; Y Yazaki; R Nagai; I Komuro
Journal:  Circulation       Date:  1999-12-14       Impact factor: 29.690

3.  Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle.

Authors:  W H duBell; S T Gaa; W J Lederer; T B Rogers
Journal:  Am J Physiol       Date:  1998-12

4.  A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.

Authors:  J D Molkentin; J R Lu; C L Antos; B Markham; J Richardson; J Robbins; S R Grant; E N Olson
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

5.  Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.

Authors:  B A Rothermel; T A McKinsey; R B Vega; R L Nicol; P Mammen; J Yang; C L Antos; J M Shelton; R Bassel-Duby; E N Olson; R S Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats.

Authors:  W Zhang; R C Kowal; F Rusnak; R A Sikkink; E N Olson; R G Victor
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

7.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure.

Authors:  T Meguro; C Hong; K Asai; G Takagi; T A McKinsey; E N Olson; S F Vatner
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

8.  Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.

Authors:  A Murat; C Pellieux; H R Brunner; T Pedrazzini
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

9.  A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type.

Authors:  E R Chin; E N Olson; J A Richardson; Q Yang; C Humphries; J M Shelton; H Wu; W Zhu; R Bassel-Duby; R S Williams
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

10.  Ambulatory blood pressure and left ventricular mass in cyclosporin- and non-cyclosporin-treated renal transplant recipients.

Authors:  G W Lipkin; B Tucker; M Giles; A E Raine
Journal:  J Hypertens       Date:  1993-04       Impact factor: 4.844
View more
  14 in total

1.  Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy.

Authors:  Rick B Vega; Beverly A Rothermel; Carla J Weinheimer; Atilla Kovacs; R H Naseem; Rhonda Bassel-Duby; R S Williams; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

Review 2.  Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.

Authors:  Timothy A McKinsey; Eric N Olson
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Modeling hypertrophic IP3 transients in the cardiac myocyte.

Authors:  Michael Cooling; Peter Hunter; Edmund J Crampin
Journal:  Biophys J       Date:  2007-08-10       Impact factor: 4.033

4.  Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant.

Authors:  Rashmi Choudhary; K P Mishra; C Subramanyam
Journal:  Indian J Clin Biochem       Date:  2006-09

5.  Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.

Authors:  Christopher L Antos; Timothy A McKinsey; Norbert Frey; William Kutschke; John McAnally; John M Shelton; James A Richardson; Joseph A Hill; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 6.  Cardiac models in drug discovery and development: a review.

Authors:  Robert K Amanfu; Jeffrey J Saucerman
Journal:  Crit Rev Biomed Eng       Date:  2011

7.  Suppression of proliferation and cardiomyocyte hypertrophy by CHAMP, a cardiac-specific RNA helicase.

Authors:  Zhi-Ping Liu; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

8.  Earliest changes in the left ventricular transcriptome postmyocardial infarction.

Authors:  Mark H Harpster; Somnath Bandyopadhyay; D Paul Thomas; Pavel S Ivanov; Jacque A Keele; Natalia Pineguina; Bifeng Gao; Vijay Amarendran; Mark Gomelsky; Richard J McCormick; Mark M Stayton
Journal:  Mamm Genome       Date:  2006-07-14       Impact factor: 2.957

9.  Eccentric exercise activates novel transcriptional regulation of hypertrophic signaling pathways not affected by hormone changes.

Authors:  Lauren G MacNeil; Simon Melov; Alan E Hubbard; Steven K Baker; Mark A Tarnopolsky
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

10.  Calcineurin activity in children with Mental handicap.

Authors:  L Hema Bindu; P Usha Rani; P P Reddy
Journal:  Indian J Clin Biochem       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.